Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of bone-protecting agents such as zoledronic acid and denosumab (Prolia, Xgeva) ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...